Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, et al. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira(R)) or continuing biosimilar therapy: week 52-92 data from a randomized, Arthritis Res Ther 2021;23:248.
PMID: 34563243